New painkiller showdown: can a Long-Acting drug beat standard care for surgery pain?
NCT ID NCT07271979
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study tests if a long-acting painkiller (liposomal bupivacaine) works better than a standard one (ropivacaine) for pain after upper abdominal surgery. About 146 adults having open surgery will receive one of the two drugs injected into the belly lining before the incision is closed. The main goal is to see which drug reduces pain scores and the need for extra pain medicine in the first 24 hours.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANALGESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qilu Hospital of Shandong University
Jinan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple playlist be the new painkiller? Music's power over surgery anxiety put to the test
- Could a playlist be the new Pre-Surgery calm?
- A shot at smoother recovery: knee replacement pain blocks put to the test
- What's the right dose? a trial seeks the sweet spot for labor epidurals
- Can a targeted nerve block replace opioids after stomach cancer surgery?
- Can a targeted nerve block cut opioid use after gallbladder surgery?